^
    Evidence Level:
    Sensitive: A1 - Approval

    [EGFR exon 19 deletion-Non Small Cell Lung Cancer-gefitinib]

    Source:
    FDA
    Test:

    therascreen® EGFR RGQ PCR Kit

    Excerpt:
    IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: A1 - Approval

    [EGFR L858R-Non Small Cell Lung Cancer-gefitinib]

    Source:
    FDA
    Test:

    therascreen® EGFR RGQ PCR Kit

    Excerpt:
    IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: A1 - Approval

    [EGFR L858R-Non Small Cell Lung Cancer-dacomitinib]

    Source:
    FDA
    Test:

    therascreen® EGFR RGQ PCR Kit

    Excerpt:
    VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: A1 - Approval

    [EGFR exon 19 deletion-Non Small Cell Lung Cancer-dacomitinib]

    Source:
    FDA
    Test:

    therascreen® EGFR RGQ PCR Kit

    Excerpt:
    VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C3 – Early Trials

    [EGFR T790M-Non Small Cell Lung Cancer-rociletinib]

    Source:
    N Engl J Med
    Test:

    therascreen® EGFR RGQ PCR Kit

    Title:
    Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
    Excerpt:
    ...T790M-positive patients treated with rociletinib in our study had a sustained clinical benefit. A response rate of 59% with prolonged disease control was noted. Although the best responses were observed among those with T790M-positive cancers, rociletinib showed some antitumor activity in patients without a documented T790M mutation.
    DOI:
    10.1056/NEJMoa1413654